In the latest trading session, 1.09 million IGM Biosciences Inc (NASDAQ:IGMS) shares changed hands as the company’s beta touched 0.21. With the company’s most recent per share price at $14.01 changed hands at -$2.53 or -15.30% at last look, the market valuation stands at $831.07M. IGMS’s current price is a discount, trading about -60.6% off its 52-week high of $22.50. The share price had its 52-week low at $3.81, which suggests the last value was 72.81% up since then. When we look at IGM Biosciences Inc’s average trading volume, we note the 10-day average is 0.62 million shares, with the 3-month average coming to 322.74K.
Analysts gave the IGM Biosciences Inc (IGMS) stock a consensus recommendation rating of Hold, calculated at a mean rating of 2.11. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended IGMS as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IGM Biosciences Inc (NASDAQ:IGMS) trade information
Instantly IGMS was in red as seen in intraday trades today. With action -17.05%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 68.59%, with the 5-day performance at -17.05% in the red. However, in the 30-day time frame, IGM Biosciences Inc (NASDAQ:IGMS) is 37.49% up. Looking at the short shares, we see there were 5.28 million shares sold at short interest cover period of 32.74 days.
The consensus price target for the stock as assigned by Wall Street analysts is 17, meaning bulls need an upside of 17.59% from its recent market value. According to analyst projections, IGMS’s forecast low is 12 with 31 as the target high. To hit the forecast high, the stock’s price needs a -121.27% plunge from its current level, while the stock would need to tank 14.35% for it to hit the projected low.
IGM Biosciences Inc (IGMS) estimates and forecasts
Data shows that the IGM Biosciences Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 53.28% over the past 6 months, a 33.55% in annual growth rate that is considerably higher than the industry average of 17.80%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -44.65%. The 2024 estimates are for IGM Biosciences Inc earnings to increase by 34.11%.
IGMS Dividends
IGM Biosciences Inc is expected to release its next quarterly earnings report on 2024-Nov-11.
IGM Biosciences Inc (NASDAQ:IGMS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 34.70% of IGM Biosciences Inc shares while 66.33% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 101.57%. There are 66.33% institutions holding the IGM Biosciences Inc stock share, with BAKER BROS. ADVISORS LP the top institutional holder. As of 2024-06-30, the company held 6.8042% of the shares, roughly 4.09 million IGMS shares worth $28.1 million.
PRICE T ROWE ASSOCIATES INC /MD/ holds the second largest percentage of outstanding shares, with 6.7789% or 4.08 million shares worth $28.0 million as of 2024-06-30.
